BioSpace News Archive

DeepUll, a medical diagnostics company developing culture-free, affordable diagnostic solutions for the early identification of sepsis and other acute infections, announces that it has appointed Richard Ivey as a non-executive director.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 178,500 shares of BioCryst common stock on September 30, 2021 as inducements material to each employee entering into employment with BioCryst.

Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it has completed the early repayment of a debenture series on which it owed C$ 1.3 million and was paying an interest rate of 9.0%.

Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, announced the Company will present data in the form of a poster presentation at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting to be held November 10-14, 2021.

Starton Therapeutics Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 16/854,810, covering STAR-LLD, the Company’s continuous delivery lenalidomide program.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced it has completed the acquisition of its new research and development center located in Frederick, Md.

Compugen Ltd. (NASDAQ: CGEN), today announced that Compugen is entitled to receive a $6 million milestone payment from AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer.

Lyra Therapeutics, Inc. announced that new, positive LYR-210 data from the LANTERN 6-month post-treatment evaluation and recently completed pharmacokinetic study, were the subject of two oral presentations at the 67th Annual Meeting of the American Rhinologic Society on October 1-2.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the enrollment of the first pediatric patient in the INHALE-1 study.

AlloVir, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to posoleucel (Viralym-M, ALVR105) for the treatment of virus-associated hemorrhagic cystitis (HC).